Literature DB >> 6324992

Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration.

L J Murphy, L C Murphy, E Vrhovsek, R L Sutherland, L Lazarus.   

Abstract

The presence of receptors for lactogenic hormones in human breast cancer tissue has been documented previously, but the relationship between the expression of these receptors and estrogen receptor (ER) status has not been adequately studied. In this report, the specificity of 125I-human growth hormone (HGH) binding in both cultured human breast cancer cell lines and tumor biopsies was studied to establish that HGH was a suitable ligand for investigating lactogenic receptor concentration in these tissues. In addition, the relationship between specific binding of 125I-HGH and ER concentration in human breast cancer was investigated. Specific 125I-HGH binding to 14 breast cancer cell lines in long term culture and to membrane preparations (microsomal and plasma membrane fractions) from 31 breast cancer biopsy specimens was examined. Human prolactin and HGH were approximately equipotent in inhibiting binding of 125I-HGH to both cultured breast cancer cell lines and to membrane preparations from breast cancer biopsy specimens. Competitive inhibition experiments using lactogenic and somatogenic hormones established that the specificity of 125I-HGH binding to breast cancer biopsy material was similar to that of cultured breast cancer cell lines and similar to that reported for subprimate lactogenic receptors. Saturable, high-affinity (Ka = 0.53 to 2.33 nM-1), low-capacity (330 to 6560 sites/cell) growth hormone binding sites were found on each of the ER-positive cell lines, whereas no specific 125I-HGH binding to ER-negative cell monolayers was detected. When all cell lines were considered, a significant linear correlation (r = 0.745, p less than 0.001) between ER and lactogenic receptor concentrations was found. Significant specific 125I-HGH binding, greater than 1% of the total radioactivity added, was detected in 20 of 31 (65%) breast tumor biopsy specimens. The mean affinity and capacity of the lactogenic receptor as measured in 8 separate membrane preparations were Ka = 0.52 +/- 0.09 (S.E.) nM-1 and 255 +/- 85 fmol/mg protein. Membrane preparations from ER-negative tumors (less than 3 fmol ER/mg cytosol protein) bound significantly less 125I-HGH than did membrane preparations from ER-positive tumor biopsies (1.22 +/- 0.44 versus 3.21 +/- 0.56%, p less than 0.05). A significant linear correlation between specifically bound 125I-HGH and ER concentration (r = 0.412, p less than 0.02) was demonstrated in the 31 breast cancer biopsy specimens studied.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6324992

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.

Authors:  H Wennbo; M Gebre-Medhin; A Gritli-Linde; C Ohlsson; O G Isaksson; J Törnell
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

2.  Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos.

Authors:  Jennifer H Gutzman; Sarah E Nikolai; Debra E Rugowski; Jyoti J Watters; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2005-03-03

3.  Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer.

Authors:  Feng Fang; Ayanna J Flegler; Pan Du; Simon Lin; Charles V Clevenger
Journal:  Am J Pathol       Date:  2008-12-04       Impact factor: 4.307

4.  The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Suzanne M Wetz; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

Review 5.  Transgenic models to study actions of prolactin in mammary neoplasia.

Authors:  Lisa M Arendt; Linda A Schuler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

6.  Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop.

Authors:  C V Clevenger; W P Chang; W Ngo; T L Pasha; K T Montone; J E Tomaszewski
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

Review 7.  What can we learn from rodents about prolactin in humans?

Authors:  Nira Ben-Jonathan; Christopher R LaPensee; Elizabeth W LaPensee
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

8.  The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors.

Authors:  G H Bakker; B Setyono-Han; J A Foekens; H Portengen; W L van Putten; F H de Jong; S W Lamberts; J C Reubi; J G Klijn
Journal:  Breast Cancer Res Treat       Date:  1990-11       Impact factor: 4.872

9.  Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study.

Authors:  S De Placido; C Gallo; F Perrone; A Marinelli; C Pagliarulo; C Carlomagno; G Petrella; M D'Istria; G Delrio; A R Bianco
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

10.  Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture.

Authors:  A Lemus-Wilson; P A Kelly; D E Blask
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.